Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 130 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cholangitis Clear all
Completed No phase listed Observational

pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

NCT01392274
View directory record Official record
Conditions
Cholangiocarcinoma, Bile Duct Inflammation
Interventions
Not listed
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
New Haven, Connecticut • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

NCT03183570
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions
[18F]FP-R01-MG-F2
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 6, 2026, 7:49 AM EDT
Terminated Not applicable Interventional

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

NCT03684187
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Mindfulness Based Intervention
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis

NCT02464020
View directory record Official record
Conditions
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease
Interventions
Vancomycin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Sep 6, 2026, 7:49 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LB-P8 low-dose, LB-P8 high-dose, Placebo
Drug
Lead sponsor
LISCure Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 6, 2026, 7:49 AM EDT
Enrolling by invitation No phase listed Observational

Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)

NCT07631442
View directory record Official record
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis

NCT02061540
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LUM001
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
La Jolla, California • Sacramento, California • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.

NCT02424175
View directory record Official record
Conditions
Sclerosing Cholangitis
Interventions
Fecal Microbiota Transplantation
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

Combination Therapy With Ursodeoxycholic Acid (UDCA) and All-Trans Retinoic Acid (ATRA) for Treatment of Primary Sclerosing Cholangitis

NCT01456468
View directory record Official record
Conditions
Cholangitis, Sclerosing
Interventions
Oral all-trans retinoic acid (ATRA)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 6, 2026, 7:49 AM EDT
Recruiting Phase 1 Interventional

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559
View directory record Official record
Conditions
Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 6, 2026, 7:49 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

NCT03995212
View directory record Official record
Conditions
Cholestatic Pruritus
Interventions
CR845 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Coronado, California • Rialto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 6, 2026, 7:49 AM EDT
Recruiting Phase 3 Interventional

Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes

NCT07216235
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Marietta, Georgia • Indianapolis, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

NCT02943460
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Cilofexor, Placebo to match cilofexor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
16
States / cities
Sacramento, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

NCT03124108
View directory record Official record
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Elafibranor 80 mg, Elafibranor 120 mg, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 1 Interventional

Treatment of IgG4-Related Disease With Revlimid and Rituximab

NCT02705638
View directory record Official record
Conditions
Immunoglobulin G Subclass 4 Related Disease, IgG4-related Disease, Autoimmune Pancreatitis, IgG4-related Sclerosing Cholangitis, Retroperitoneal Fibrosis
Interventions
Rituximab, Lenalidomide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2019 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC)

NCT02978339
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Curcumin
Drug
Lead sponsor
John E. Eaton
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 6, 2026, 7:49 AM EDT
Terminated Phase 2 Interventional Results available

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

NCT03394781
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
DUR-928
Drug
Lead sponsor
Durect
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
San Francisco, California • Jacksonville, Florida • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 6, 2026, 7:49 AM EDT
Completed No phase listed Observational

Cholangioscopy in Primary Sclerosing Cholangitis (PSC)

NCT03766035
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
SpyGlass DS I - II
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Davis, California • Sacramento, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 6, 2026, 7:49 AM EDT
Not yet recruiting No phase listed Observational

PET/MRI of Primary Sclerosing Cholangitis

NCT06252610
View directory record Official record
Conditions
PSC
Interventions
Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)

NCT04480840
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
21
States / cities
Pasadena, California • Redwood City, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 6, 2026, 7:49 AM EDT
Withdrawn No phase listed Observational

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05293938
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Obeticholic Acid 5 MG, Obeticholic Acid 10 MG, Standard of Care: UDCA
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 6, 2026, 7:49 AM EDT
Completed No phase listed Observational

A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)

NCT07049887
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 2 Interventional Results available

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

NCT05239468
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 6, 2026, 7:49 AM EDT
Completed Phase 3 Interventional Results available

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

NCT03602560
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
seladelpar 5-10 mg, seladelpar 10 mg, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
51
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Sep 6, 2026, 7:49 AM EDT